Phase 2 trials showed up to 24% body weight reduction the highest observed for any obesity compound to date positioning it as the frontier compound in metabolic research
CagriSema vs Semaglutide (Wegovy) CagriSema vs Retatrutide Retatrutide is Eli Lillys investigational triple-agonist (GLP-1, GIP, and glucagon)
To preserve muscle mass, patients should: Hit their daily protein target Spread protein evenly across meals Include protein before bed, such as Greek yogurt or cottage cheese Perform resistance training 23 times per week Protein before bed may support overnight muscle protein synthesis
Lather up and brighten up
Carobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M, et al
But in 2025 and 2026, the agency issued over 80 warning letters to companies marketing compounded or unapproved GLP-1 products with misleading claims